Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Accumulated Expenses (2020 - 2025)

PROCEPT BioRobotics has reported Accumulated Expenses over the past 6 years, most recently at $23.2 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $23.2 million for Q4 2025, up 7.61% from a year ago — trailing twelve months through Dec 2025 was $23.2 million (up 7.61% YoY), and the annual figure for FY2025 was $23.2 million, up 7.61%.
  • Accumulated Expenses for Q4 2025 was $23.2 million at PROCEPT BioRobotics, up from $21.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PRCT hit a ceiling of $23.2 million in Q4 2025 and a floor of $4.6 million in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $13.4 million (2022), compared with a mean of $13.2 million.
  • Biggest five-year swings in Accumulated Expenses: surged 110.95% in 2022 and later grew 7.61% in 2025.
  • PROCEPT BioRobotics' Accumulated Expenses stood at $6.5 million in 2021, then surged by 107.68% to $13.4 million in 2022, then grew by 25.57% to $16.9 million in 2023, then grew by 27.55% to $21.5 million in 2024, then grew by 7.61% to $23.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $23.2 million (Q4 2025), $21.8 million (Q3 2025), and $16.3 million (Q2 2025) per Business Quant data.